Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14172MR)

This product GTTS-WQ14172MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14172MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7932MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ2579MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ1908MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGN 150998
GTTS-WQ14126MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ562MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ15784MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ4232MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ359MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW